16.13
0.25 (1.57%)
| Previous Close | 15.88 |
| Open | 15.81 |
| Volume | 2,735 |
| Avg. Volume (3M) | 1,779 |
| Market Cap | 1,582,825,472 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | 70.24% |
| Diluted EPS (TTM) | -1.08 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 108.23% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | 61.15 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -26.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ARROWHEAD PHARMACEUTICALS INC A | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 77.19% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |